Amoéba Authorisation for large-scale greenhouse trials in the Netherlands
Amoéba has received an exceptional exemption in the Netherlands for large-scale greenhouse trials with its biocontrol product, Axpera, allowing the crops to be consumed. The authorisation could help validate Axpera's effectiveness under commercial conditions and potentially speed up the commercial rollout once formal EU approval has been obtained. We see strong potential in Amoéba's amoeba lysate in both biocontrol and cosmetics, hence reiterate our Buy rating with a € 1.7 TP.Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.